[Experimental study of the effects on proliferation and apoptosis of A549 cell line of adenocarcinoma of the lung with compatibility of Radix ex Rhizoma ginseng and Fafces Trogopterori].
OBJECTIVE
To observe the effects of the compatibility of Radix ex Rhizoma Ginseng and Fafces Trogopterori on proliferation and apoptosis of A549 cell line of adenocarcinoma of the lung, to clarify the mechanism, to explore the best proportion compatibility, and to offer the reasonable experiment evidence in clinical medicine therapy.


METHODS
Twenty-five healthy Wistar rats were divided into five groups randomly, 5 rats in each group, including normal group, Radix ex Rhizoma Ginseng and Fafces Trogopterori in the ratio of 1:1 group, 1:2 group, 2:1 group, and complex recipe of beetle capsule group. After the pharmacy liquor was decocted, equivalent dose for rat was calculated. According to the weights, all rats were intragastric administrated at the standard of 1 mL x 100 g(-1), twice a day, continuously for 3 days. One hour after the last administration, the serum was collected and mixed with culture media RPMI 1640 to prepare the drug serum incubation liquid at the concentration of 10%. MTT was used to measure the growth curve and the inhibition rate of tumor cell, and the apoptosis was observed by electron microscope.


RESULTS
The compatibility of Radix ex Rhizoma Ginseng and Fafces Trogopterori could inhibit the cell proliferation of cell line A549 of lung adenocarcinoma and have an inducement on apoptosis. The effect was significant in the ratio of 2:1.


CONCLUSIONS
These results indicate that inhibiting the proliferation and inducing the apoptosis of tumor cell may be one of the anticancer mechanism of the compatibility of Radix ex Rhizoma Ginseng and Fafces Trogopterori.
Wang
Jin
J
Liaoning College of Traditional Chinese Medicine, Shenyang 110032, China.
Ren
Yan-Ling
YL
D000230:Adenocarcinoma / Q000473:pathology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004344:Drug Incompatibility; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000494:pharmacology*; D005260:Female; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008419:Materia Medica / Q000494:pharmacology*; D005894:Panax / Q000737:chemistry; D010946:Plants, Medicinal / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004365:Drugs, Chinese Herbal; D008419:Materia Medica